Context-dependent duality of senescent cells in liver fibrosis

Abstract

Liver fibrosis, marked by excessive deposition of extracellular matrix (ECM), is a critical precursor to cirrhosis, liver failure, and hepatocellular carcinoma. Accumulating evidence highlights that cellular senescence, characterized by stable cell-cycle arrest and senescence-associated secretory phenotypes (SASPs), is a key regulator of the fibrotic process. This review systematically dissects the context-dependent roles of senescent cells in liver fibrosis, with a focus on hepatocytes, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs), Kupffer cells, and natural killer (NK) cells. Distinct populations of senescent cells emerge sequentially during different stages of fibrosis, exhibiting divergent kinetics and functional effects. The SASP, a dynamic cocktail composed of cytokines, chemokines, and proteases, remodels the intrahepatic microenvironment through immune cell recruitment, regulation of cell function, and modulation of ECM turnover. These effects vary depending on their molecular composition and disease context. Furthermore, we discuss emerging senescence-targeted therapeutic strategies to restore liver homeostasis. In-depth understanding of the cell-type and stage-specific roles of senescence in fibrosis provides a molecular foundation for translating senescence-targeted strategies into clinical precision antifibrotic therapies.

Keywords

Cellular senescence / Liver fibrosis / Hepatic stellate cell (HSC) / Senescence-associated secretory phenotype (SASP) / Antifibrotic therapy

References

[1] Friedman SL. Liver fibrosis —from bench to bedside. J Hepatol. 2003; 38(Suppl 1):S38-S53. https://doi.org/10.1016/s0168—8278(02)00429—4.

[2] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021; 18:151-166. https://doi.org/10.1038/s41575—020—00372—7.

[3] Yang W, He H, Wang T, et al. Single—cell transcriptomic analysis reveals a hepatic stellate cell—activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology. 2021; 74:2774-2790. https://doi.org/10.1002/hep.31987.

[4] Filliol A, Saito Y, Nair A, et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature. 2022; 610:356-365. https://doi.org/10.1038/s41586—022—05289—6.

[5] Zhao M, Wang L, Wang M, et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther . 2022; 7:206. https://doi.org/10.1038/s41392—022—01070—3.

[6] Du K, Umbaugh DS, Wang L, et al. Targeting senescent hepatocytes for treatment of metabolic dysfunction—associated steatotic liver disease and multi—organ dysfunction. Nat Commun. 2025; 16:3038. https://doi.org/10.1038/s41467—025—57616—w.

[7] Gu L, Zhao C, Wang Y, et al. Hepatic stellate cells by specific delivery of manganese for limiting liver fibrosis. Nano Lett . 2024; 24:1062-1073. https://doi.org/10.1021/acs.nanolett.3c03689.

[8] Tu C, Qian C, Li S, et al. Targeting the chromatin remodeler BAZ2B mitigates hepatic senescence and MASH fibrosis. Nat Aging. 2025; 5:1063-1078. https://doi.org/10.1038/s43587—025—00862—w.

[9] López—Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell . 2023; 186:243-278. https://doi.org/10.1016/j.cell.2022.11.001.

[10] Sanfeliu—Redondo D, Gibert—Ramos A, Gracia—Sancho J. Cell senescence in liver diseases: pathological mechanism and theranostic opportunity. Nat Rev Gastroenterol Hepatol. 2024; 21:477-492. https://doi.org/10.1038/s41575—024—00913—4.

[11] Zhao H, Liu Z, Chen H, et al. Identifying specific functional roles for senescence across cell types. Cell . 2024; 187:7314-7334(e21). https://doi.org/10.1016/j.cell.2024.09.021.

[12] Karpova A, Li X, Peng CW, et al. Cellular senescence in human liver under normal aging and cancer. Cell Genom . 2026; 6:101133. https://doi.org/10.1016/j.xgen.2025.101133.

[13] Du K, Jun JH, Dutta RK, Diehl AM. Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology. Hepatol Commun. 2024; 8:e0411. https://doi.org/10.1097/hc9.0000000000000411.

[14] Krizhanovsky V, Yon M, Dickins R, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134:657-667. https://doi.org/10.1016/j.cell.2008.06.049.

[15] Zare Jalise S, Habibi S, Khosrowpour Z, et al. Liver regeneration: polyploidy and cellular senescence as potential regulators. Stem Cell Rev Rep . 2026; 22:275-295. https://doi.org/10.1007/s12015—025—11001—8.

[16] Du K, Umbaugh DS, Ren N, Diehl AM. Cellular senescence in liver diseases: from molecular drivers to therapeutic targeting. J Hepatol . 2026; 84:194-212. https://doi.org/10.1016/j.jhep.2025.08.021.

[17] He K, Zhou D, Pu Z, et al. Cellular senescence in acute liver injury: what happens to the young liver? Aging Dis . 2024; 16:1347-1362. https://doi.org/10.14336/ad.2024.0586.

[18] Kumar S, Duan Q, Wu R, Harris EN, Su Q. Pathophysiological communication between hepatocytes and non—parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev . 2021; 176:113869. https://doi.org/10.1016/j.addr.2021.113869.

[19] Kong X, Feng D, Wang H, et al. Interleukin—22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology . 2012; 56:1150-1159. https://doi.org/10.1002/hep.25744.

[20] McConnell MJ, Kostallari E, Ibrahim SH, Iwakiri Y. The evolving role of liver sinusoidal endothelial cells in liver health and disease. Hepatology. 2023; 78:649-669. https://doi.org/10.1097/HEP.0000000000000207.

[21] Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740. https://doi.org/10.1038/nrm2233.

[22] Majewska J, Krizhanovsky V. Immune surveillance of senescent cells in aging and disease. Nat Aging. 2025; 5:1415-1424. https://doi.org/10.1038/s43587—025—00910—5.

[23] Wei P, Zhang X, Yan C, Sun S, Chen Z, Lin F. Mitochondrial dysfunction and aging: multidimensional mechanisms and therapeutic strategies. Biogerontology . 2025; 26:142. https://doi.org/10.1007/s10522—025—10273—4.

[24] Jia L, Yang Y, Sun F, Tao H, Lu C, Yang JJ. Mitochondrial quality control in liver fibrosis: epigenetic hallmarks and therapeutic strategies. Cell Signal. 2024; 115:111035. https://doi.org/10.1016/j.cellsig.2024.111035.

[25] Gong J, Tu W, Liu J, Tian D. Hepatocytes: a key role in liver inflammation. Front Immunol . 2022; 13:1083780. https://doi.org/10.3389/fimmu.2022.1083780.

[26] Amengual J, Alay A, Vaquero J, et al. Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression. Cell Death Dis. 2024; 15:680. https://doi.org/10.1038/s41419—024—07063—0.

[27] Penrice DD, Jalan—Sakrikar N, Jurk D, Passos J, Simonetto DA. Telomere dysfunction in chronic liver disease: the link from aging.Hepatology . 2024; 80:951-964. https://doi.org/10.1097/HEP.0000000000000426.

[28] Liang Y, Kaushal D, Wilson RB. Cellular senescence and extracellular vesicles in the pathogenesis and treatment of obesity: a narrative review. Int J Mol Sci . 2024; 25:7943. https://doi.org/10.3390/ijms25147943.

[29] Ni HM, Woolbright BL, Williams J, et al. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol. 2014; 61:617-625. https://doi.org/10.1016/j.jhep.2014.04.043.

[30] Wang B, Han J, Elisseeff JH, Demaria M. The senescence—associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024; 25:958-978. https://doi.org/10.1038/s41580—024—00727—x.

[31] Zang J, Ye J, Zhang C, Sha M, Gao J. Senescent hepatocytes enhance natural killer cell activity via the CXCL—10/CXCR3 axis. Exp Ther Med. 2019; 18:3845-3852. https://doi.org/10.3892/etm.2019.8037.

[32] Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre—malignant hepatocytes limits liver cancer development. Nature. 2011; 479:547-551. https://doi.org/10.1038/nature10599.

[33] Wijayasiri P, Astbury S, Kaye P, et al. Role of hepatocyte senescence in the activation of hepatic stellate cells and liver fibrosis progression. Cells. 2022; 11:2221. https://doi.org/10.3390/cells11142221.

[34] Irvine KM, Skoien R, Bokil NJ, et al. Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. World J Gastroenterol. 2014; 20:17851-17862. https://doi.org/10.3748/wjg.v20.i47.17851.

[35] Huang Y, Yang X, Meng Y, et al. The hepatic senescence—associated secretory phenotype promotes hepatocarcinogenesis through Bcl3—dependent activation of macrophages. Cell Biosci . 2021; 11:173. https://doi.org/10.1186/s13578—021—00683—5.

[36] Akkiz H, Gieseler RK, Canbay A. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells. Int J Mol Sci. 2024; 25:7873. https://doi.org/10.3390/ijms25147873.

[37] Yashaswini CN, Qin T, Bhattacharya D, et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction—associated steatohepatitis. J Hepatol. 2024; 81:207-217. https://doi.org/10.1016/j.jhep.2024.03.014.

[38] Wu Q, Leng X, Zhang Q, et al. IRF3 activates RB to authorize cGAS—STING—induced senescence and mitigate liver fibrosis. Sci Adv. 2024; 10:eadj2102. https://doi.org/10.1126/sciadv.adj2102.

[39] Cabral—Pacheco GA, Garza—Veloz I, Castruita—De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci . 2020; 21:9739. https://doi.org/10.3390/ijms21249739.

[40] Pereira BI, Devine OP, Vukmanovic—Stejic M, et al. Senescent cells evade immune clearance via HLA—E—mediated NK and CD8(+) T cell inhibition. Nat Commun. 2019; 10:2387. https://doi.org/10.1038/s41467—019—10335—5.

[41] Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024; 81:895-910. https://doi.org/10.1016/j.jhep.2024.06.016.

[42] Meijnikman AS, Herrema H, Scheithauer TPM, Kroon J, Nieuwdorp M, Groen AK. Evaluating causality of cellular senescence in non—alcoholic fatty liver disease. JHEP Rep. 2021; 3:100301. https://doi.org/10.1016/j.jhepr.2021.100301.

[43] Fei B, Wang H, Ding Y, et al. Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs. Mater Today Bio. 2025; 33:101996. https://doi.org/10.1016/j.mtbio.2025.101996.

[44] Zhou Y, Zhang L, Ma Y, et al. Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis—fibrotic progression to hepatocellular carcinoma. Theranostics. 2023; 13:4430-4448. https://doi.org/10.7150/thno.85369.

[45] Sun Y, Weng J, Chen X, et al. Oroxylin A activates ferritinophagy to induce hepatic stellate cell senescence against hepatic fibrosis by regulating cGAS—STING pathway. Biomed Pharmacother. 2023; 162:114653. https://doi.org/10.1016/j.biopha.2023.114653.

[46] Liu H, Dong F, Li G, et al. Liuweiwuling tablets attenuate BDL—induced hepatic fibrosis via modulation of TGF—beta/Smad and NF—kappaB signaling pathways. J Ethnopharmacol. 2018; 210:232-241. https://doi.org/10.1016/j.jep.2017.08.029.

[47] Duan JL, Ruan B, Yan XC, et al. Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice. Hepatology. 2018; 68:677-690. https://doi.org/10.1002/hep.29834.

[48] Gracia—Sancho J, Caparrós E, Fernández—Iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol. 2021; 18:411-431. https://doi.org/10.1038/s41575—020—00411—3.

[49] Lao Y, Li Y, Zhang P, et al. Targeting endothelial Erk1/2—Akt axis as a regeneration strategy to bypass fibrosis during chronic liver injury in mice. Mol Ther. 2018; 26:2779-2797. https://doi.org/10.1016/j.ymthe.2018.08.016.

[50] Ojha U, Kim S, Rhee CY, et al. Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis. Hepatology. 2025; 81:1228-1243. https://doi.org/10.1097/hep.0000000000001018.

[51] Dai Q, Ain Q, Seth N, Zhao H, Rooney M, Zipprich A. Aging—associated liver sinusoidal endothelial cells dysfunction aggravates the progression of metabolic dysfunction—associated steatotic liver disease. Aging Cell. 2025; 24:e14502. https://doi.org/10.1111/acel.14502.

[52] Behmoaras J, Gil J. Similarities and interplay between senescent cells and macrophages. J Cell Biol . 2020; 220:e202010162. https://doi.org/10.1083/jcb.202010162.

[53] Chen J, Xu T, Zhu D, et al. Egg antigen p40 of Schistosoma japonicum promotes senescence in activated hepatic stellate cells by activation of the STAT3/p53/p21 pathway.Cell Death Dis . 2016; 7:e2315. https://doi.org/10.1038/cddis.2016.228.

[54] Wan J, Benkdane M, Alons E, Lotersztajn S, Pavoine C. M2 kupffer cells promote hepatocyte senescence: an IL—6—dependent protective mechanism against alcoholic liver disease. Am J Pathol . 2014; 184:1763-1772. https://doi.org/10.1016/j.ajpath.2014.02.014.

[55] Peng M, Li N, Wang H, et al. Macrophages: subtypes, distribution, polarization, immunomodulatory functions, and therapeutics. MedComm . 2025; 6:e70304. https://doi.org/10.1002/mco2.70304.

[56] Speziali E, Aranha C, Teixeira—Carvalho A, et al. Ageing down—modulates liver inflammatory immune responses to schistosome infection in mice. Scand J Immunol . 2010; 71:240-248. https://doi.org/10.1111/j.1365—3083.2010.02370.x.

[57] Sato A, Nakashima H, Nakashima M, et al. Involvement of the TNF and FasL produced by CD11b Kupffer cells/macrophages in CCl4—induced acute hepatic injury. PLoS One . 2014; 9:e92515. https://doi.org/10.1371/journal.pone.0092515.

[58] Che Z, Zhou Z, Li SQ, Gao L, Xiao J, Wong NK. ROS/RNS as molecular signatures of chronic liver diseases. Trends Mol Med. 2023; 29:951-967. https://doi.org/10.1016/j.molmed.2023.08.001.

[59] Pedroza—Diaz J, Arroyave—Ospina JC, Serna Salas S, Moshage H. Modulation of oxidative stress—induced senescence during non—alcoholic fatty liver disease. Antioxidants . 2022; 11:975. https://doi.org/10.3390/antiox11050975.

[60] Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene. 2013; 32:1971-1977. https://doi.org/10.1038/onc.2012.206.

[61] Sagiv A, Burton DG, Moshayev Z, et al. NKG2D ligands mediate immunosurveillance of senescent cells. Aging (Albany NY) . 2016; 8:328-344. https://doi.org/10.18632/aging.100897.

[62] Amer J, Salhab A, Safadi R. Rosuvastatin restores liver tissue—resident NK cell activation in aged mice by improving mitochondrial function. Biomed Pharmacother. 2025; 186:118000. https://doi.org/10.1016/j.biopha.2025.118000.

[63] Abu—Tair L, Axelrod JH, Doron S, et al. Natural killer cell—dependent antifibrotic pathway in liver injury via toll—like receptor—9. PLoS One . 2013; 8:e82571. https://doi.org/10.1371/journal.pone.0082571.

[64] Polo ML, Ghiglione YA, Salido JP, et al. Liver cirrhosis in HIV/HCV—coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4+ T—cells. J Int AIDS Soc. 2019; 22:e25375. https://doi.org/10.1002/jia2.25375.

[65] Wallace SJ, Tacke F, Schwabe RF, Henderson NC. Understanding the cellular interactome of non—alcoholic fatty liver disease. JHEP Rep. 2022; 4:100524. https://doi.org/10.1016/j.jhepr.2022.100524.

[66] Iltis C, Moskalevska I, Debiesse A, et al. A ganglioside—based immune checkpoint enables senescent cells to evade immunosurveillance during aging. Nat Aging. 2025; 5:219-236. https://doi.org/10.1038/s43587—024—00776—z.

[67] Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013; 15:978-990. https://doi.org/10.1038/ncb2784.

[68] Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X. STING—mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Investig. 2019; 129:546-555. https://doi.org/10.1172/jci121842.

[69] Alqahtani S, Alqahtani T, Venkatesan K, et al. SASP modulation for cellular rejuvenation and tissue homeostasis: therapeutic strategies and molecular insights.Cells . 2025; 14:608. https://doi.org/10.3390/cells14080608.

[70] Sun F, Wang J, Sun Q, et al. Interleukin—8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38:449. https://doi.org/10.1186/s13046—019—1455—x.

[71] Lee HS, Miau LH, Chen CH, et al. Differential role of p38 in IL—1alpha induction of MMP—9 and MMP—13 in an established liver myofibroblast cell line. J Biomed Sci. 2003; 10:757-765. https://doi.org/10.1159/000073963.

[72] Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59:583-594. https://doi.org/10.1016/j.jhep.2013.03.033.

[73] Dewidar B, Meyer C, Dooley S, Meindl—Beinker AN. TGF—β in hepatic stellate cell activation and liver fibrogenesis: updated 2019. Cells . 2019; 8:1419. https://doi.org/10.3390/cells8111419.

[74] Engelmann C, Tacke F. The potential role of cellular senescence in non—alcoholic fatty liver disease. Int J Mol Sci . 2022; 23:652. https://doi.org/10.3390/ijms23020652.

[75] Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18:1028-1040. https://doi.org/10.1038/nm.2807.

[76] Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu Rev Immunol. 2010; 28:321-342. https://doi.org/10.1146/annurev—immunol—030409—101311.

[77] Schaefer L. Complexity of danger: the diverse nature of damage—associated molecular patterns. J Biol Chem. 2014; 289:35237-35245. https://doi.org/10.1074/jbc.R114.619304.

[78] Sagiv A, Krizhanovsky V. Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology . 2013; 14:617-628. https://doi.org/10.1007/s10522—013—9473—0.

[79] Matsuda S, Revandkar A, Dubash TD, et al. TGF—beta in the microenvironment induces a physiologically occurring immune—suppressive senescent state. Cell Rep. 2023; 42:112129. https://doi.org/10.1016/j.celrep.2023.112129.

[80] Wu KJ, Qian QF, Zhou JR, et al. Regulatory T cells (Tregs) in liver fibrosis. Cell Death Discov . 2023; 9:53. https://doi.org/10.1038/s41420—023—01347—8.

[81] Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Investig. 2013; 123:966-972. https://doi.org/10.1172/JCI64098.

[82] Lopes—Paciencia S, Saint—Germain E, Rowell MC, Ruiz AF, Kalegari P, Ferbeyre G. The senescence—associated secretory phenotype and its regulation. Cytokine. 2019; 117:15-22. https://doi.org/10.1016/j.cyto.2019.01.013.

[83] Sun XF, Gu L, Deng WS, Xu Q. Impaired balance of T helper 17/T regulatory cells in carbon tetrachloride—induced liver fibrosis in mice. World J Gastroenterol . 2014; 20:2062-2070. https://doi.org/10.3748/wjg.v20.i8.2062.

[84] He S, Sharpless NE. Senescence in health and disease. Cell. 2017; 169:1000-1011. https://doi.org/10.1016/j.cell.2017.05.015.

[85] Prata L, Ovsyannikova IG, Tchkonia T, Kirkland JL. Senescent cell clearance by the immune system: emerging therapeutic opportunities. Semin Immunol. 2018; 40:101275. https://doi.org/10.1016/j.smim.2019.04.003.

[86] Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs . 2016; 21:343-357. https://doi.org/10.1080/14728214.2016.1220533.

[87] Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human—centric approach. Nat Rev Gastroenterol Hepatol. 2023; 20:679-688. https://doi.org/10.1038/s41575—023—00796—x.

[88] Huang Y, Liu T. Step further towards targeted senolytic therapy: therapeutic potential of uPAR—CAR T cells for senescence—related diseases. Signal Transduct Targeted Ther. 2020; 5:155. https://doi.org/10.1038/s41392—020—00268—7.

[89] Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence—associated pathologies. Nature. 2020; 583:127-132. https://doi.org/10.1038/s41586—020—2403—9.

[90] Luo X, Jiang X, Li J, et al. Insulin—like growth factor—1 attenuates oxidative stress—induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53—progerin interaction. Cell Death Dis. 2019; 10:451. https://doi.org/10.1038/s41419—019—1670—6.

[91] Hou X, Li Z, Higashi Y, Delafontaine P, Sukhanov S. Insulin—like growth factor I prevents cellular aging via activation of mitophagy. J Aging Res. 2020; 2020:4939310. https://doi.org/10.1155/2020/4939310.

[92] Gui R, Li W, Li Z, et al. Effects and potential mechanisms of IGF1/IGF1R in the liver fibrosis: a review. Int J Biol Macromol . 2023; 251:126263. https://doi.org/10.1016/j.ijbiomac.2023.126263.

[93] Nishikawa T, Ohtomo N, Inoue Y, et al. Insulin—like growth factor—I reduces collagen production by hepatic stellate cells through stimulation of collagen degradation system via mTOR—dependent signaling pathway. Biomedicines. 2025; 13:566. https://doi.org/10.3390/biomedicines13030566.

[94] Tian Q, Zhang Q, Wang B, Qian Y, Liu F. IGF1/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC.Discov Oncol . 2025; 16:1058. https://doi.org/10.1007/s12672—025—02890—9.

[95] Ma X, Luo Q, Zhu H, et al. Aldehyde dehydrogenase 2 activation ameliorates CCl(4)—induced chronic liver fibrosis in mice by up—regulating Nrf2/HO—1 antioxidant pathway. J Cell Mol Med. 2018; 22:3965-3978. https://doi.org/10.1111/jcmm.13677.

[96] Ding X, Zhu XL, Xu DH, et al. NPM promotes hepatotoxin—induced fibrosis by inhibiting ROS—induced apoptosis of hepatic stellate cells and upregulating lncMIAT—induced TGF—β2. Cell Death Dis . 2023; 14:575. https://doi.org/10.1038/s41419—023—06043—0.

[97] Wu D, Cederbaum AI. Inhibition of autophagy promotes CYP2E1—dependent toxicity in HepG2 cells via elevated oxidative stress, mitochondria dysfunction and activation of p38 and JNK MAPK. Redox Biol . 2013; 1:552-565. https://doi.org/10.1016/j.redox.2013.10.008.

[98] Fortier M, Cadoux M, Boussetta N, et al. Hepatospecific ablation of p38α MAPK governs liver regeneration through modulation of inflammatory response to CCl(4)—induced acute injury. Sci Rep. 2019; 9:14614. https://doi.org/10.1038/s41598—019—51175—z.

[99] Wang TW, Johmura Y, Suzuki N, et al. Blocking PD—L1—PD—1 improves senescence surveillance and ageing phenotypes. Nature. 2022; 611:358-364. https://doi.org/10.1038/s41586—022—05388—4.

[100] Yue M, Li C, Li G. New advances in the study of PD—1/PD—L1 inhibitors—induced liver injury. Int Immunopharmacol. 2024; 131:111799. https://doi.org/10.1016/j.intimp.2024.111799.

[101] Du K, Maeso—Díaz R, Oh SH, et al. Targeting YAP—mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 2023; 77:1998-2015. https://doi.org/10.1097/hep.0000000000000326.

[102] Maeso—Díaz R, Ortega—Ribera M, Lafoz E, et al. Aging influences hepatic microvascular biology and liver fibrosis in advanced chronic liver disease. Aging Dis. 2019; 10:684-698. https://doi.org/10.14336/ad.2019.0127.

[103] Hu Y, Yang B, Xiao C, et al. Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis. Cell . 2026; 189:2663-2683. https://doi.org/10.1016/j.cell.2026.02.001.

[104] Boyer—Diaz Z, Aristu—Zabalza P, Andrés—Rozas M, et al. Pan—PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021; 74:1188-1199. https://doi.org/10.1016/j.jhep.2020.11.045.

[105] Liu W, Liu Y, Zhang L, et al. Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis. Nat Commun. 2025; 16:4517. https://doi.org/10.1038/s41467—025—59885—x.

[106] Yang M, Vanderwert E, Kimchi ET, Staveley—O'Carroll KF, Li G. The important roles of natural killer cells in liver fibrosis. Biomedicines. 2023; 11:1391. https://doi.org/10.3390/biomedicines11051391.

[107] Dewidar B, Meyer C, Dooley S, Meindl—Beinker AN. TGF—beta in hepatic stellate cell activation and liver ribrogenesis—updated 2019. Cells. 2019; 8:1419. https://doi.org/10.3390/cells8111419.

[108] Jiang Y, Cai R, Huang Y, et al. Macrophages in organ fibrosis: from pathogenesis to therapeutic targets. Cell Death Discov . 2024; 10:487. https://doi.org/10.1038/s41420—024—02247—1.

[109] Liu Z, Ren J, Qiu C, Wang Y, Zhang T. Application of mesenchymal stem cells in liver fibrosis and regeneration. Liver Res. 2024; 8:246-258. https://doi.org/10.1016/j.livres.2024.11.004.

[110] Niu H, Wang YN, Ding Y, Lin YQ, Qin J, Wang JC. Stem cell—based therapeutic strategies for liver aging. Liver Res. 2025; 9:118-131. https://doi.org/10.1016/j.livres.2025.04.003.

[111] Cheng N, Kim KH, Lau LF. Senescent hepatic stellate cells promote liver regeneration through IL—6 and ligands of CXCR2. JCI Insight. 2022; 7:e158207. https://doi.org/10.1172/jci.insight.158207.

[112] Wang MJ, Zhang HL, Chen F, Guo XJ, Liu QG, Hou J. The double—edged effects of IL—6 in liver regeneration, aging, inflammation, and diseases. Exp Hematol Oncol . 2024; 13:62. https://doi.org/10.1186/s40164—024—00527—1.

[113] Rigual MDM, Sánchez Sánchez P, Djouder N. Is liver regeneration key in hepatocellular carcinoma development? Trends Cancer. 2023; 9:140-157. https://doi.org/10.1016/j.trecan.2022.10.005.